乳腺癌新辅助化疗-局部区域治疗适应证的背景。
Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.
机构信息
Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany.
出版信息
Strahlenther Onkol. 2018 Sep;194(9):797-805. doi: 10.1007/s00066-018-1329-8. Epub 2018 Jul 4.
Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology.
新辅助化疗（NACT）已广泛应用于乳腺癌的多学科综合治疗。治疗反应的预后影响已得到明确证实。然而，治疗反应对辅助放疗适应证的影响尚不清楚。本文从放射肿瘤学的角度综述了 NACT 及治疗反应对复发风险和局部区域多学科管理的重要影响。
Zotero 插件